Mesgarpour B, Heidinger B, Roth D, Schmitz S, Walsh C, Herkner H
Cochrane Database Syst Rev. 2017; 8:CD010969.
PMID: 28841235
PMC: 6373621.
DOI: 10.1002/14651858.CD010969.pub2.
Babiker F
Med Princ Pract. 2015; 25 Suppl 1:22-8.
PMID: 25966896
PMC: 5588518.
DOI: 10.1159/000381916.
Gholamzadeh A, Amini S, Mohammadpour A, Vahabzadeh M, Fazelifar A, Fazlinezhad A
J Cardiovasc Pharmacol. 2015; 65(6):555-61.
PMID: 25636071
PMC: 4461390.
DOI: 10.1097/FJC.0000000000000223.
Mesgarpour B, Heidinger B, Schwameis M, Kienbacher C, Walsh C, Schmitz S
Intensive Care Med. 2013; 39(11):1896-908.
PMID: 23928897
DOI: 10.1007/s00134-013-3030-9.
Talan M, Latini R
Methods Mol Biol. 2013; 982:265-302.
PMID: 23456875
PMC: 6207951.
DOI: 10.1007/978-1-62703-308-4_17.
Did clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window?.
Talan M, Ahmet I, Lakatta E
PLoS One. 2012; 7(4):e34819.
PMID: 22529941
PMC: 3329541.
DOI: 10.1371/journal.pone.0034819.
Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review.
Li J, Xu H, Gao Q, Wen Y
Eur J Clin Pharmacol. 2011; 68(5):469-77.
PMID: 22086550
DOI: 10.1007/s00228-011-1160-y.
Acute coronary syndromes: the unfulfilled promise of erythropoietin in patients with MI.
van der Meer P, Van Veldhuisen D
Nat Rev Cardiol. 2011; 8(8):425-6.
PMID: 21709702
DOI: 10.1038/nrcardio.2011.102.
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.
Najjar S, Rao S, Melloni C, Raman S, Povsic T, Melton L
JAMA. 2011; 305(18):1863-72.
PMID: 21558517
PMC: 3486644.
DOI: 10.1001/jama.2011.592.
Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond.
Sanganalmath S, Abdel-Latif A, Bolli R, Xuan Y, Dawn B
Basic Res Cardiol. 2011; 106(5):709-33.
PMID: 21541807
PMC: 4281455.
DOI: 10.1007/s00395-011-0183-y.
Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial.
Melloni C, Rao S, Povsic T, Melton L, Kim R, Kilaru R
Am Heart J. 2010; 160(5):795-803.e2.
PMID: 21095264
PMC: 3018783.
DOI: 10.1016/j.ahj.2010.09.007.
Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial.
Tang Y, Hasan F, Giordano F, Pfau S, Rinder H, Katz S
Am Heart J. 2009; 158(6):941-7.
PMID: 19958860
PMC: 2838229.
DOI: 10.1016/j.ahj.2009.06.032.
Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS).
Andreotti F, Agati L, Conti E, Santucci E, Rio T, Tarantino F
J Thromb Thrombolysis. 2009; 28(4):489-95.
PMID: 19533304
DOI: 10.1007/s11239-009-0363-x.
Novel pharmacotherapies to abrogate postinfarction ventricular remodeling.
Dorn 2nd G
Nat Rev Cardiol. 2009; 6(4):283-91.
PMID: 19352332
DOI: 10.1038/nrcardio.2009.12.
